Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on innovative treatments for pattern hair loss. Its lead program, VDPHL01, is a proprietary extended-release oral minoxidil tablet studied for mild-to-moderate androgenetic alopecia. The company aims to build a focused portfolio of aesthetic dermatology candidates for common, under-served skin and hair conditions. As a clinical-stage firm with negligible product sales, value hinges on pipeline progress rather than commercial operations.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -18 | — |
| Q3 2025 | 0 | — | -22.6 | — |
| Q4 2025 | 0 | — | -28.2 | — |
| Q1 2026 | 0 | — | -30 | — |
| Q2 2026 | 0 | — | -23.5 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: BILL Holdings, Inc. (BILL), Signet Jewelers Limited (SIG), Clear Secure, Inc. (YOU), OPENLANE, Inc. (OPLN), Vontier Corporation (VNT), Radian Group Inc. (RDN)